Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Observational

Village-Based Management of Chronic Cardiovascular Disease in Qu Jiang Elderly Population Registry: The BOUQUET Cohort Study

NCT07149688 · tracked via the Priya Life Science China tracker
Phase
Observational
Started
2024-03-01
Last updated
2025-09-02

Condition(s) studied

Atrial Fibrillation (AF)HypertensionCoronary Heart Disease (CHD)Heart Failure

Investigational drug(s) / intervention(s)

Comprehensive management program (pharmacologic treatment, lifestyle modification, health education, structured follow-up)

Comprehensive management program (pharmacologic treatment, lifestyle modification, health education, structured follow-up): Comprehensive management program (pharmacologic treatment, lifestyle modification, health education, structured follow-up) Enhanced monitoring with 7-day ECG

Study summary

This is a prospective observational cohort study conducted in Qujiang District, Zhejiang Province, China, aiming to evaluate the effectiveness of a comprehensive management program for elderly patients with chronic cardiovascular diseases (CVDs). The program integrates pharmacological treatment, lifestyle modification, health education, and long-term follow-up, with enhanced monitoring using 7-day ECG recording. The study focuses on major chronic CVDs including hypertension, coronary artery disease, atrial fibrillation, and heart failure. Approximately 30,000 participants aged ≥60 years will be enrolled and followed for up to 10 years.

Eligibility

Sex
ALL
Min age
60 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria Age ≥60 years Resident of Qujiang District Diagnosed with chronic CVD (hypertension, coronary artery disease, heart failure, atrial fibrillation, or others) Able and willing to provide informed consent Exclusion Criteria Severe cognitive impairment or inability to provide consent Life expectancy \<1 year due to non-cardiovascular disease Participation refusal

Primary outcome measure(s)

  • Incidence of cardiovascular events — 10 years
    Incidence of cardiovascular events (myocardial infarction, stroke, hospitalization for heart failure, cardiovascular death) - assessed annually during follow-up
  • All-cause and cardiovascular mortality — 10 years
    All-cause and cardiovascular mortality - assessed at 10 years

Trial sites (1)

FacilityCityRegionStatus
Beijing Anzhen Hospital Beijing Beijing Municipality Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07149688 on ClinicalTrials.gov ↗ ← All trials in China